A Phase I clinical trial published in The Lancet has shown that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This is the first time live stem cells have been used on a fetus’s damaged spine, which could potentially lead to better health outcomes for babies compared to traditional fetal surgery.
Continue Reading this article here
